Robert J. Hayashi, M.D.  hayashi_r@kids.wustl.edu

Division Chief, Hematology and Oncology
Researcher, Patient Oriented Research Unit
Patient Oriented Research UnitHematology and Oncology

phone: (314) 454-6018

Clinical Interests

Dr. Hayashi is Chief of the Division of Pediatric Hematology/Oncology and an attending physician in Hematology/Oncology and General Pediatrics at St. Louis Children’s Hospital. Dr. Hayashi is board certified in both Pediatrics and Pediatric Hematology/Oncology with clinical interests that include Bone Marrow Transplantation, Non-Hodgkin's Lymphoma and Post-transplant Lymphoproliferative disease (PTLD) and the long term consequences of cancer therapy. He is actively involved in institutional national trials advancing the treatment of patients in these areas.

Education

  • BS, Departmental Honors, Stanford University1982
  • MD, Washington Unversity School of Medicine1986

Training

  • Intern in Pediatrics, St. Louis Chiildren's Hospital1986 - 1987
  • Resident in Pediatrics , St. Louis Children's Hospital1987 - 1989
  • Fellowship in Pediatric Hematology/Oncology, The Johns Hopkins School of Medicine 1989 - 1992

Licensure and Board Certification

  • American Board of Pediatrics 1991
  • Pediatric Hematology/Oncology 1992
  • MO, Missouri Medical Licensure 1994

Honors

  • Departmental Honors, Department of Biology, Stanford University, Stanford California1982
  • Child Health Research Center Award1990 - 1992
  • Physicain Scientist Award1992 - 1997
  • Castle Connolly's America's Top Doctors in Cancer2005 - Pres
  • Castle Connolly's America's Top Doctors2006 - Pres
  • Legacy Award, National Children's Cancer Society2006
  • Medical Excellence Award, National Childrens Cancer Society2013

Recent Publications view all (69)


Publication Co-Authors

  1. Increased complications of chronic erythrocytapheresis compared with manual exchange transfusions in children and adolescents with sickle cell disease. Pediatr Blood Cancer. 2017. PMID:28544309 
  2. Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplant. Biol Blood Marrow Transplant. 2017. PMID:28527984 
  3. Survival and Late Effects after Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancy at Less Than Three Years of Age. Biol Blood Marrow Transplant. 2017. PMID:28461213 
  4. Improved survival after acute graft vs host disease diagnosis in the modern era. Haematologica. 2017. PMID:28302712 
  5. Challenges Evaluating Chemotherapy-Induced Peripheral Neuropathy in Childhood Cancer Survivors. J Pediatr Oncol Nurs. 2017;34(2):106-114. PMID:27251891 
  6. Cognitive, behaviour, and academic functioning in adolescent and young adult survivors of childhood acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study. Lancet Psychiatry. 2016;3(10):965-972. PMCID:PMC5056029  PMID:27639661 
  7. Response to: "Technology and Long-Term Health-Related Quality-of-Life Outcomes in Children with Nonmalignant Disorders after Reduced-Intensity Conditioning and Stem Cell Transplantation". Biol Blood Marrow Transplant. 2016;22(9):1734. PMID:27343717 
  8. Long-Term Follow-Up after Reduced-Intensity Conditioning and Stem Cell Transplantation for Childhood Nonmalignant Disorders. Biol Blood Marrow Transplant. 2016. doi:10.1016/j.bbmt.2016.04.025  PMID:27164064 
  9. Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2016;48(1):101. PMID:26711114 
  10. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015. doi:10.1038/ng.3400  PMID:26457647 
  11. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol. 2015. doi:10.1002/ajh.24183  PMID:26348869 
  12. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.08.023  PMID:26327632 
  13. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. Bone Marrow Transplant. 2015. doi:10.1038/bmt.2015.177  PMID:26237164 
  14. Tacrolimus versus Cyclosporine after Hematopoietic Cell Transplantation for Acquired Aplastic Anemia. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.05.023  PMID:26033280 
  15. The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.05.010  PMID:25981509 
  16. Neurocognitive outcomes and school performance in solid tumor cancer survivors lacking therapy to the central nervous system. J Pers Med. 2015;5(2):83-90. doi:10.3390/jpm5020083  PMID:25867598 
  17. Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning Is Successful in Children with Hematologic Cytopenias of Genetic Origin. Biol Blood Marrow Transplant. 2015. doi:10.1016/j.bbmt.2015.03.019  PMID:25840334 
  18. Secondary solid cancer screening following hematopoietic cell transplantation. Bone Marrow Transplant. 2015. doi:10.1038/bmt.2015.63  PMID:25822223 
  19. Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia. Pediatr Blood Cancer. 2015. doi:10.1002/pbc.25458  PMID:25755151 
  20. Late toxicity of a novel allogeneic stem cell transplant using single fraction total body irradiation for hematologic malignancies in children. J Pediatr Hematol Oncol. 2015;37(2):e94-e101. doi:10.1097/MPH.0000000000000272  PMID:25333837 
  21. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2015;21(2):266-74. doi:10.1016/j.bbmt.2014.10.021  PMCID:PMC4326247  PMID:25445023 
  22. Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2015;21(1):151-8. doi:10.1016/j.bbmt.2014.10.006  PMCID:PMC4272862  PMID:25316109 
  23. Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014. doi:10.1016/j.bbmt.2014.07.009  PMID:25042734 
  24. Adolescent and young adult oncology, version 2.2014. J Natl Compr Canc Netw. 2014;12(1):21-32; quiz 32. PMID:24453290 
  25. Participation and Self -Management Strategies of Young Adult Cancer Survivors Occupational Therapy Journal of Research. 2013;33(1):21-30. 
  26. A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood. Neuro Oncol. 2013. doi:10.1093/neuonc/not021  PMID:23460318 
  27. Second malignancies after autologous hematopoietic cell transplantation in children. Bone Marrow Transplant. 2013;48(3):363-8. doi:10.1038/bmt.2012.166  PMCID:PMC3525761  PMID:22964594 
  28. Differential effects of radiotherapy on growth and endocrine function among acute leukemia survivors: a childhood cancer survivor study report. Pediatr Blood Cancer. 2013;60(1):110-5. doi:10.1002/pbc.24198  PMCID:PMC3436954  PMID:22628201 
  29. Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report. Am J Transplant. 2012;12(11):3069-75. doi:10.1111/j.1600-6143.2012.04206.x  PMCID:PMC3484187  PMID:22883417 
  30. Adolescent and young adult oncology. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2012;10(9):1112-50. PMID:22956810 
  31. Adolescent and young adult oncology. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2012;10(9):1112-50. PMID:22956810 
  32. Blueberry Muffin Rash and REspiratory Distress in a Late Preterm INfant Neoreviews. 2012;13:e506. 
  33. Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens. J Pediatr Hematol Oncol. 2010;32(2):119-23. doi:10.1097/MPH.0b013e3181cb8593  PMID:20098336 
  34. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010;16(2):223-30. doi:10.1016/j.bbmt.2009.09.021  PMCID:PMC2911354  PMID:19800015 
  35. Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2010;54(2):291-8. doi:10.1002/pbc.22227  PMID:19743300 
  36. Impact of radiation and chemotherapy on risk of dental abnormalities: a report from the Childhood Cancer Survivor Study. Cancer. 2009;115(24):5817-27. doi:10.1002/cncr.24670  PMID:19834960 
  37. The Late-Effects of Childhood Cancer on Occupational Performance and Quality of Life: A Pilot Study Occupational Therapy Journal of Research . 2009;29(3):116-124. 
  38. Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI. Bone Marrow Transplant. 2009;43(4):307-14. doi:10.1038/bmt.2008.327  PMCID:PMC2792985  PMID:19011666 
  39. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant. 2008;42(3):175-80. doi:10.1038/bmt.2008.133  PMID:18454181 
  40. Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood. 2008;111(8):4014-21. doi:10.1182/blood-2007-08-106021  PMCID:PMC2288716  PMID:18258798 
  41. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol. 2008;58(4):575-8. doi:10.1016/j.jaad.2007.12.037  PMID:18249465 
  42. Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol. 2008;30(2):130-4. doi:10.1097/MPH.0b013e31815d1d83  PMID:18376265 
  43. Allogeneic hematopoietic cell transplantation (HCT) in Hurler's syndrome using a reduced intensity preparative regimen. Bone Marrow Transplant. 2008;41(4):349-53. doi:10.1038/sj.bmt.1705926  PMID:18026148 
  44. Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients. Pediatr Transplant. 2007;11(3):312-8. doi:10.1111/j.1399-3046.2006.00626.x  PMCID:PMC1930168  PMID:17430489 
  45. Physical impairment and social adaptation in adult survivors of childhood and adolescent rhabdomyosarcoma: A report from the Childhood Cancer Survivors Study. Psychooncology. 2007;16(1):26-37. doi:10.1002/pon.1072  PMID:16921476 
  46. Requirement of high-affinity IL-2-IL-2R interaction for T cell anergy induction. Int Immunol. 2006;18(5):645-51. doi:10.1093/intimm/dxh397  PMID:16574670 
  47. Otolaryngological manifestations of posttransplant lymphoproliferative disorder in pediatric thoracic transplant patients. Int J Pediatr Otorhinolaryngol. 2006;70(2):303-10. doi:10.1016/j.ijporl.2005.07.011  PMID:16125255 
  48. Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003. Bone Marrow Transplant. 2005;35(4):361-7. doi:10.1038/sj.bmt.1704743  PMID:15608659 
  49. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant. 2005;35(4):345-52. doi:10.1038/sj.bmt.1704795  PMID:15592491 
  50. Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med. 2005;7(2):143-6. doi:10.109701.GIM.0000154299.22120.6A  PMID:15714083 
  51. Isolated CNS relapse following stem cell transplantation for juvenile myelomonocytic leukemia. J Pediatr Hematol Oncol. 2003;25(11):910-3. PMID:14608204 
  52. Phase 1 study of Paclitaxel administered twice weekly to children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol. 2003;25(7):539-42. PMID:12847320 
  53. Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation. 2003;75(9):1538-43. doi:10.1097/01.TP.0000061607.07985.BD  PMID:12792511 
  54. Childhood cancer survivors' knowledge about their past diagnosis and treatment: Childhood Cancer Survivor Study. JAMA. 2002;287(14):1832-9. PMID:11939869 
  55. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol. 2001;19(15):3463-9. PMID:11481351 
  56. Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR Am J Roentgenol. 2001;177(2):449-54. doi:10.2214/ajr.177.2.1770449  PMID:11461881 
  57. Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin. Bone Marrow Transplant. 2001;27(10):1059-64. doi:10.1038/sj.bmt.1703032  PMID:11438821 
  58. Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. J Pediatr Hematol Oncol. 2001;23(1):14-8. PMID:11196263 
  59. Posttransplantation lymphoproliferative disorder in children: clinical, histopathologic, and imaging features. Radiology. 2000;217(1):16-25. PMID:11012419 
  60. High incidence of posttransplant lymphoproliferative disease in pediatric patients with cystic fibrosis. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1252-5. doi:10.1164/ajrccm.161.4.9901013  PMID:10764320 
  61. Unique CD4(+) T cells in TCR alpha chain-deficient class I MHC-restricted TCR transgenic mice: role in a superantigen-mediated disease process. Int Immunol. 1999;11(9):1581-90. PMID:10464179 
  62. The central role of CD4(+) T cells in the antitumor immune response. J Exp Med. 1998;188(12):2357-68. PMCID:PMC2212434  PMID:9858522 
  63. Chest radiography as a predictor of outcome in posttransplantation lymphoproliferative disorder in lung allograft recipients. AJR Am J Roentgenol. 1998;171(2):375-82. doi:10.2214/ajr.171.2.9694455  PMID:9694455 
  64. Differences between responses of naive and activated T cells to anergy induction. J Immunol. 1998;160(1):33-8. PMID:9551953 
  65. Cytogenetic abnormalities in two cases of neuroblastoma. Cancer Genet Cytogenet. 1994;74(1):30-4. PMID:8194044 
  66. In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med. 1994;179(4):1215-24. PMCID:PMC2191440  PMID:7908321 
  67. Primitive neuroectodermal tumor arising in the pancreas. Mod Pathol. 1994;7(2):200-4. PMID:7911997 
  68. Identification of Igh-C-linked determinants on suppressor T cell hybrids and factors specific for L-glutamic acid60-L-alanine30-L-tyrosine10 (GAT). J Exp Med. 1985;162(3):1044-59. PMCID:PMC2187798  PMID:2411840 
  69. Regulation of biogenic amine methyltransferases by glucocorticoids via S-adenosylmethionine and its metabolizing enzymes, methionine adenosyltransferase and S-adenosylhomocysteine hydrolase. Brain Res. 1985;330(2):209-16. PMID:2985192 
Last updated: 08/10/2017
Wash U School of Medicine
Children's Hospital St. Louis
Children's Discovery Institute
© 2017 by Washington University in St. Louis
One Brookings Drive, St. Louis, MO 63130